[BREAKING] Hemerion obtains the FDA clearance for its next US clinical trial

Hemerion wins the Réseau Entreprendre® award

Hemerion is one of the 2020 laureates of the Réseau Entreprendre®, the first international private network of business leaders, with 126 locations worldwide, grouped in 65 associations.

Hemerion wins Hodéfi award

Hemerion is one of the winners designated by Hodéfi, an association that finances and supports innovative companies in the Hauts-de-France region, and has received one of its first grants.

Therapeutic Innovation Prize

Hemerion wins the therapeutic innovation prize awarded by HDFID, an economic development and innovation agency supported by the Hauts de France Region.

Technology transfer

SATT Nord, a specialist in technology transfer from public research laboratories, grants Hemerion Therapeutics an exclusive license to exploit the anti-cancer technology co-developed by INSERM, the University of Lille and the Lille University Hospital.

Galien Prize MedStartup

Hemerion awarded the Galien MedStartup Prize

Hemerion and Mount Sinai Health System (NYC) are collaborating to launch an ambitious clinical trial in 2022. This project has won the “Best Collaboration in the MedTech and Digital Health” award of the Galien Medstartup Prize: an international recognition that perfectly kickstarts the Hemerion development in the USA. Read more – Press release

Hemerion Technology

Hemerion gathers 1.5M€ in funding

For its preliminary funding round, Hemerion gathers 1.5M€ in dilutive and non-dilutive funding to further validate its therapeutic approach.